Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2002

View Archived Issues

New licensing agreement signed by JT for JTE-522

Systemic antitumor response follows s.c. or intrahepatic suicide cell-based vaccination

New antedrugs with therapeutic potential in psoriasis

Potential therapeutic agent for Chagas' disease enters development

Natural plant pigment exerts chemopreventive effects in mouse colon cancer model

Wyeth-Ayerst engineers new transgenic rat model for ALS research

Vernalis and Roche collaborate on diabetes drug development

Morphine-sparing analgesic effects demonstrated for valdecoxib in knee replacement surgery trial

Shareholder approval for Millennium and Cor Therapeutics merger

aaiPharma licenses rights to Tanatril in U.S.

FDA approves BioStratum's IND for antiangiogenesis agent

CCL's Aspirair technology incorporated into Vectura business

AVI BioPharma licenses calicivirus patent

Patient enrollment begins for ALVAC-CEA/B7.1 study in colorectal cancer

Discovery Therapeutics changes name to Aderis

TAK-457 may be more effective than amphotericin B as Rx for invasive pulmonary aspergillosis

Preparation and use of new glucagon receptor antagonists/inverse agonists patented by Novo Nordisk

Pfizer synthesizes JAK3 inhibitors potentially useful as immunosuppressants

Recent patent discloses NMDA NR2B antagonists designed at Merck

Novel factor Xa inhibitors for treatment of thromboembolic disorders

Eisai seeks FDA clearance for new indication of Aciphex/Pariet

Tripeptide prodrugs of therapeutic agents with improved toxicity profile prepared at Corixa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.